ClinicalTrials.Veeva

Menu

Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients

E

Ege University

Status

Completed

Conditions

Xerostomia
Sjögren's Syndrome

Treatments

Drug: Hydroxychloroquine

Study type

Observational

Funder types

Other

Identifiers

NCT00873496
EAlpoz 1

Details and patient eligibility

About

Chronic inflammation that comprises the exocrine glands' function leads to xerophthalmia and xerostomia in Sjögren's syndrome. The oral consequences range widely and they are related to decreased salivary output. Hydroxychloroquine may inhibit cholinesterase activity in salivary glands via interference with antigen processing mechanism, and thus, the investigators' hypothesis was that salivary gland function may be improved if treated with hydroxychloroquine. The effects of hydroxychloroquine on the salivary flow rate, subjective and objective parameters of the patients were also assessed.

Enrollment

30 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who were recently diagnosed with primary SS according to American-European criteria and who were scheduled for HCQ treatment in Ege University Faculty of Medicine, Department of Rheumatology

Exclusion criteria

  • Sjögren patients consuming alcohol or tobacco

Trial design

30 participants in 1 patient group

Sjögren
Description:
Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
Treatment:
Drug: Hydroxychloroquine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems